CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
For the period ended Sep 26, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 26, 2026 · Filed Nov 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
The following table provides information relating to the purchases of shares of our common stock during the three months ended September 26, 2026.
| Total Numberof SharesPurchased · AveragePrice Paidper Share · Total Number ofShares Purchasedas Part of PubliclyAnnounced Plansor Programs · Approximate DollarValue of SharesThat May Yet BePurchased Underthe Plans or Programs | |||||
|---|---|---|---|---|---|
| (in thousands) | |||||
| June 28, 2026 to July 25, 2026 | 165 | $227.14 | — | $700,000 | |
| July 26, 2026 to August 22, 2026 | 179 | 232.51 | — | 700,000 | |
| August 23, 2026 to September 26, 2026 | 80 | 288.77 | — | 700,000 | |
| Total | 424 | — | |||
On October 29, 2025, our Board of Directors approved, in aggregate, a stock repurchase program of $1.0 billion. During the three months ended September 26, 2026, we did not repurchase any shares of common stock under our stock repurchase program. As of September 26, 2026, we had $700.0 million remaining on the authorized $1.0 billion stock repurchase program.
Additionally, our stock-based compensation plans permit the netting of common stock upon vesting of restricted stock units, and performance share units in order to satisfy individual statutory tax withholding requirements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.